Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

New phase III trial of loteprednol etabonate for allergic rhinitis

Aug. 21, 2003

Selective iNOS inhibitors show potential in the treatment of endotoxin-induced uveitis

Aug. 21, 2003

Phase IIIb results support use of diquafosol in dry eye

Aug. 20, 2003

AlphaCor introduction for cornea transplant patients who reject human tissue

Aug. 20, 2003

Santen seeks Japanese manufacturing approval for vernal keratoconjunctivitis treatment

Aug. 18, 2003

ISTA files second Vitrase NDA

Aug. 7, 2003

Squalamine improves visual outcomes in phase I/II wet AMD study

Aug. 6, 2003

Priority review for diquafosol tetrasodium NDA

Aug. 5, 2003

IGF-I peptides useful in ophthalmology and dermatology

Aug. 4, 2003

IOP-lowering agents prepared and tested by Alcon researchers

July 28, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...